Short Interest Runner: Today Aquinox Pharmaceuticals Incorporated (NASDAQ:AQXP) Reported Increase in Shorted Shares

November 24, 2016 - By Dolores Ford   ·   0 Comments

Short Interest Runner: Today Aquinox Pharmaceuticals Incorporated (NASDAQ:AQXP) Reported Increase in Shorted Shares

The stock of Aquinox Pharmaceuticals Incorporated (NASDAQ:AQXP) registered an increase of 4.82% in short interest. AQXP’s total short interest was 2.70 million shares in November as published by FINRA. Its up 4.82% from 2.58 million shares, reported previously. With 166,400 shares average volume, it will take short sellers 16 days to cover their AQXP’s short positions. The short interest to Aquinox Pharmaceuticals Incorporated’s float is 37.21%. The stock increased 2.92% or $0.41 on November 23, hitting $14.46. About 81,368 shares traded hands. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has risen 58.73% since April 22, 2016 and is uptrending. It has outperformed by 53.32% the S&P500.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The company has a market cap of $341.77 million. The Firm operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. It currently has negative earnings. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 -containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells.

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Ratings Coverage

Out of 5 analysts covering Aquinox Pharma (NASDAQ:AQXP), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Aquinox Pharma has been the topic of 6 analyst reports since September 11, 2015 according to StockzIntelligence Inc. Canaccord Genuity maintained Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) on Friday, September 11 with “Hold” rating. The rating was initiated by Guggenheim with “Buy” on Tuesday, October 6. The firm has “Outperform” rating given on Monday, September 21 by Leerink Swann. The firm has “Hold” rating given on Tuesday, March 15 by Jefferies. The stock of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) earned “Buy” rating by Needham on Friday, October 23. The company was maintained on Friday, August 5 by Jefferies.

AQXP Company Profile

Aquinox Pharmaceuticals, Inc., incorporated on May 25, 2007, is a clinical-stage pharmaceutical firm discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Firm operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Firm is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial investigating the ability of over 200 milligrams oral, once daily AQX-1125 to reduce pain and urinary symptoms in female patients with IC/BPS.

More news for Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) were recently published by: Marketwatch.com, which released: “Aquinox stock rockets 2000%, Twitter goes nuts” on August 10, 2015. Globenewswire.com‘s article titled: “Aquinox Pharmaceuticals Announces Second Quarter 2016 Financial Results” and published on August 04, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>